Federal expansion Partnership with Lovell Government Services to expand access to rheumatoid arthritis therapy across federal healthcare systems indicates a clear path for selling to government channels and VA/DoD procurement programs.

Clinical momentum Active participation in major conferences and plans to present new clinical data at ACR Convergence signals ongoing validation of the neuroimmune platform and opportunities to engage clinical decision-makers and researchers.

Commercial readiness Significant private financing and strategic investments from major players (Boston Scientific, Abbott) alongside new hires in market access and reimbursement show a strong push toward U.S. commercialization and payer engagement.

Payer strategy Expansion of market access leadership and reimbursement expertise indicates a focus on navigating reimbursement landscapes, which aligns with timing for coverage negotiations and payer-facing value demonstrations.

Targeted competitive edge Integrated neurostimulation for rheumatoid arthritis positions SetPoint in a specialized niche with potential cross-sell opportunities to related autoimmune indications and to medtech partners seeking portfolio synergy.